Current measures of health and disease are often insensitive, episodic, and subjective. Further, these measures generally are not designed to provide meaningful feedback to individuals. The impact of high-resolution activity data collected from mobile phones is only beginning to be explored. Here we present data from mPower, a clinical observational study about Parkinson disease conducted purely through an iPhone app interface. The study interrogated aspects of this movement disorder through surveys and frequent sensor-based recordings from participants with and without Parkinson disease. Benefitting from large enrollment and repeated measurements on many individuals, these data may help establish baseline variability of real-world activity measurement collected via mobile phones, and ultimately may lead to quantification of the ebbs-and-flows of Parkinson symptoms. App source code for these data collection modules are available through an open source license for use in studies of other conditions. We hope that releasing data contributed by engaged research participants will seed a new community of analysts working collaboratively on understanding mobile health data to advance human health.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776701PMC
http://dx.doi.org/10.1038/sdata.2016.11DOI Listing

Publication Analysis

Top Keywords

parkinson disease
12
study parkinson
8
data collected
8
collected mobile
8
mobile phones
8
data
7
mpower study
4
parkinson
4
disease
4
mobile
4

Similar Publications

Objective: Pharmacoresistant tremors, often seen in Parkinson disease and essential tremor, significantly impair patient quality of life. Although deep brain stimulation has been effective, its invasive nature limits its applicability. MR-guided focused ultrasound (MRgFUS) thalamotomy offers a noninvasive alternative, but its cognitive impacts are not fully understood.

View Article and Find Full Text PDF

Previously, we reported that α-synuclein (α-syn) clusters synaptic vesicles (SV) Diao et al., 2013, and neutral phospholipid lysophosphatidylcholine (LPC) can mediate this clustering Lai et al., 2023.

View Article and Find Full Text PDF

The centenarian blueprint: lessons in defying Parkinson's disease.

J Neural Transm (Vienna)

December 2024

Department of Neurology, Clinical Research Centre, Saiseikai Imabari Hospital, Ehime, 799- 1592, Japan.

Recent advancements in neurology have shifted focus from mere diagnosis to comprehensive management of movement disorders, particularly Parkinson's Disease (PD), which is rapidly increasing in prevalence due to global ageing trends. While age is a key risk factor for PD, centenarians often exhibit a remarkably low prevalence of the disease, presenting an intriguing paradox. This viewpoint explores potential reasons for this low prevalence, drawing on studies from regions with high centenarian populations, known as Blue Zones.

View Article and Find Full Text PDF

Parkinson's disease (PD) is accompanied by a complex array of nonmotor and motor manifestations. The exploration of anti-inflammatory and antioxidant active ingredient as potential therapeutic interventions in PD-associated mood alterations has gained significant attention. This study aimed to assess the antidepressant and anxiolytic properties of luteolin (LTN), a potent antioxidant and anti-inflammatory component, using a 6-hydroxydopamine (6-OHDA)-induced animal model of PD.

View Article and Find Full Text PDF

Differences in Blood and Cerebrospinal Fluid Between Parkinson's Disease and Related Diseases.

Cell Mol Neurobiol

December 2024

Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

It is difficult to distinguish Parkinson's disease (PD) in the early stage from those of various disorders including atypical Parkinson's syndrome (APS), vascular parkinsonism (VP), and even essential tremor (ET), because of the overlap of symptoms. Other, more challenging problems will arise when Parkinson's disease develops into Parkinson's disease dementia (PDD) in the middle and late stages. At this time, the differential diagnosis of PDD and DLB becomes thorny.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!